The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2010Physiological and Pathological Implications of the Unique Subcellular Distribution of LRRK2
Objective/Rationale:
Mutations in the LRRK2 gene are now recognized as the most common genetic cause of Parkinson’s disease, responsible for not only several inherited forms of this movement disorder... -
MJFF Research Grant, 2010Parkinson's Disease NeuroEPIC: A Study of Genes and the Environment
Objective/Rationale:
We will take advantage of the large European Prospective Investigation in Cancer (EPIC), a unique resource involving almost 500,000 participants from 10 European countries, with... -
Novel Approaches to Drug Discovery, 2010Optimizing Metalloporphryins for Clinical Development Supplement
Promising Outcomes of Original Grant:
The overall goal of this ongoing proposal is to determine if a newly developed series of metalloporphyrins designed to penetrate blood brain barrier shows promise... -
MJFF Research Grant, 2010Technology for Clinicogenetic Studies of LRRK2 G2019S in Tunisia
Objective/Rationale:
We seek to create and enhance a secure database, accessible by collaborators with customizable, user-friendly, web-based entry for clinical, genetic and pedigree information. This... -
MJFF Research Grant, 2010The Parkinson's Progression Markers Initiative (PPMI)
Objective/Rationale:
Currently there is no definitive diagnostic test for Parkinson’s disease (PD) in a live patient, and no way to track disease progression on a biological level. These gaps have... -
Rapid Response Innovation Awards, 2010Testing Whether Alpha-Synuclein is Modified by 4-hydroxy-2-nonenal in the Human Brain
Promising Outcomes of Original Grant:
The major goal of our grant application was to test whether a protein known as alpha-synuclein becomes toxic to dopamine-secreting nerve cells when it is modified...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.